Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-09-23
2009-10-06
Weber, Jon P (Department: 1657)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C424S094500, C435S015000, C435S183000, C435S194000, C514S414000
Reexamination Certificate
active
07598288
ABSTRACT:
The use of inhibitors of GSK-3 useful for treating glaucoma is disclosed.
REFERENCES:
patent: 5681854 (1997-10-01), Pang et al.
patent: 5856517 (1999-01-01), Huryn et al.
patent: 5891901 (1999-04-01), Dhingra et al.
patent: 6057117 (2000-05-01), Harrison et al.
patent: 6255485 (2001-07-01), Gray et al.
patent: 6441053 (2002-08-01), Klein et al.
patent: 6844335 (2005-01-01), Garcia et al.
patent: 39 14764 (1990-11-01), None
patent: 40 05 969 (1991-08-01), None
patent: 40 05 970 (1991-08-01), None
patent: 42 17 964 (1993-12-01), None
patent: 42 43 321 (1994-06-01), None
patent: 0 328 026 (1989-02-01), None
patent: 0 384 349 (1990-02-01), None
patent: 0 397 060 (1990-05-01), None
patent: 0 470 490 (1991-07-01), None
patent: 0 508 792 (1992-04-01), None
patent: 0 540 956 (1992-10-01), None
patent: WO 93/18765 (1993-09-01), None
patent: WO 93/18766 (1993-09-01), None
patent: WO 95/07910 (1995-03-01), None
patent: WO 96/04906 (1996-02-01), None
patent: WO 98/04551 (1998-02-01), None
patent: WO 98/04552 (1998-02-01), None
patent: WO 98/11102 (1998-03-01), None
patent: WO 98/11103 (1998-03-01), None
patent: WO 99/42100 (1999-08-01), None
patent: WO 99/62503 (1999-12-01), None
patent: WO 99/62503 (1999-12-01), None
patent: WO 00/21927 (2000-04-01), None
patent: WO 00/21927 (2000-04-01), None
patent: WO 00/38675 (2000-07-01), None
patent: WO 01/09106 (2001-02-01), None
patent: WO 01/37819 (2001-05-01), None
patent: WO 01/37819 (2001-05-01), None
patent: WO 01/41768 (2001-06-01), None
patent: WO 01/47533 (2001-07-01), None
patent: WO 01/47533 (2001-07-01), None
patent: WO 01/56567 (2001-08-01), None
patent: WO 01/64949 (2001-09-01), None
patent: WO 01/64949 (2001-09-01), None
patent: WO 01/70727 (2001-09-01), None
patent: WO 03/027116 (2003-04-01), None
patent: WO 03/027116 (2003-04-01), None
Hoffman et al. (1999.Pharmacodynamic Aspects of Modes of Drug Administration for Optimization of Drug Therapy. Critical Reviews in Therapeutic Drug Carrier Systems, vol. 16, Issue 6, pp. 1-70.
Bafico et al., “Interaction of Frizzled Related Protein (FRP) with Wnt Ligands and the Frizzled Receptor Suggests Alternative Mechanisms for FRP Inhibition of Wnt Signaling”, J. Biol. Chem., 274(23):16180-16187 (1999).
Berggren, Lennart, “The Intraocular Pressure In Rabbits After Lithium Administration With Comments On Pressure Effects Of Injections Into The Vitreous”, Acta Ophthalmologica, 45:229-238 (1967).
Bournat et al., “Wnt-1 Dependent Activation of the Survival Factor NF-•B in PC12 Cells”, Journal of Neuroscience Research, 61:21-32 (2000).
Chang et al., “Cloning and characterization of a secreted frizzled-related protein that is expressed by the retinal pigment epithelium”, Human Molecular Genetics, 4:575-583 (1999).
Chen et al., “The Mood-Stabilizing Agent Valproate Inhibits the Activity of Glycogen Synthase Kinases-3”, Journal of Neurochemistry, 72:1327-1330 (1999).
Coghlan et al., “Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription”, Chem. & Bio., 7(10):793-803 (2000).
Cross et al., “Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death”, J. Neurochem., 77:94-102 (2001).
He et al., “Glycogen Synthase Kinase 3• and Extracellular Signal-Regulated Kinase Inactivate Heat Shock Transcription Factor 1 by Facilitating the Disappearance of Transcriptionally Active Granules after Heat Shock”, Molecular and Celluar Biology, 18:6624-33 (1998).
Hers et al., “The protein kinase C inhibitors bisindolylmaleimide I (GF 1092303x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity”, FEBS Letters, 460:433-436 (1999) listed as Tavaré et al. in appln.
Husain and Abdel-Latif, “Effects of Prostaglandin F2• and Carbachol and MAP Kinases, Cytosolic Phospholipase A2 and Arachidonic Acid Release in Cat Iris Sphincter Smooth Muscle Cells”, Exp. Eye Res., 72:581-590(2001).
Jones et al., “Altered Expression of Secreted Frizzled-Related Protein-2 in Retinitis Pigmentosa Retinas”, Investigative Ophthalmology and Visual Science, 41:1297-1301 (2000).
Jones et al., “Modulated expression of secreted Frizzled-related proteins in human retinaldegeneration”, Neuroreport, 11:3963-3967 (2000).
Kaufman et al., “Ocular effects of oral lithium in humans”, ACTA Ophthalmologica, 63:327-332 (1985).
Leclerc et al., “Indirubins Inhibit Glycogen Synthase Kinase-3β and CDK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Diseases”, J. Biol. Chem., 276(1):251-260 (2001) listed as Garnier et al. in appln.
Leost et al., “Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25”, Eur. J. Biochem., 267:5983-5994 (2001).
Lucas JJ, et al., “Decreased nuclear •-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3• conditional transgenic mice”, The EMBO Journal 20(1):27-39 (2001).
Meijer et al., “Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constitutent”, Chem. & Bio., 7:51-63 (2000) Listed as Thunnissen et al. in application.
Ryves, WJ and Harwood AJ, “Lithium Inhibits Glycogen Synthase Kinase-3 by Competition for Magnesium”,Biochemical Biophysics Research Communications, 280:720-725 (2001).
Smith et al., “3-Anilino-4-arylmaleimides: Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 (GSK-3)”, Bioorganic & Med. Chem. Letters, 11 :635-639 (2001).
Tong et al., “Activation of glycogen synthase kinase 3 beta (GSK-3β) by platelet activating factor mediates migration and cell death in cerebellar granule neurons”, European Journal of Neuroscience, 13:1913-1922 (2001).
Craig et al., “Glaulcoma Genetics: Where are we? Where will we go?”, Current Opinion in Ophthalmology, 10(2):126-134 (1999).
EP 02799603.2 Supplementary European Search Report dated May 7, 2007.
Clark Abbot F.
Hellberg Mark R.
Hellberg Peggy Elizabeth
McNatt Loretta Graves
Pang Iok-Hou
Alcon Inc.
Schultz Teresa J.
Srivastava Kailash C
Weber Jon P
LandOfFree
Inhibitors of glycogen synthase kinase-3 (GSK-3) for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of glycogen synthase kinase-3 (GSK-3) for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of glycogen synthase kinase-3 (GSK-3) for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4080690